L. Newell

发表

CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy.

D. Gandara, R. O’Donnell, D. Pearson, 2012, Cancer research.

Tumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15.

D. Stirewalt, J. Hansen, E. Petersdorf, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

PlGF enhances TLR‐dependent inflammatory responses in human mononuclear phagocytes

J. Tyner, I. Burd, L. Newell, 2017, American journal of reproductive immunology.

Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years.

U. Borate, E. Traer, R. Maziarz, 2019, Hematology/oncology and stem cell therapy.

Donor and Recipient Plasma Follistatin Levels are Associated with Acute Graft-versus-Host Disease in Blood and Marrow Transplant Clinical Trials Network 0402

G. Vercellotti, M. MacMillan, Juan Wu, 2017, Bone Marrow Transplantation.

Circulating Angiogenic Factors Associated with Response and Survival in Patients with Acute Graft-Versus-Host Disease: Results from BMT CTN 0302 and 0802 Biol Blood Marrow Transplant .

Gabrielle, Meyers, G. Vercellotti, 2015 .

Engrafted donor-derived clonal hematopoiesis after allogenic hematopoietic cell transplantation is associated with chronic GVHD requiring immunosuppressive therapy, but no adverse impact on OS or relapse.

Philipp W. Raess, E. Traer, P. Raess, 2021, Transplantation and cellular therapy.

Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells.

B. Storer, T. Panzarella, M. Aljurf, 2016, Blood.

Alternative donor hematopoietic stem cell transplantation: A role for umbilical cord blood transplantation for hematologic malignancies

L. Newell, J. Gutman, C. Delaney, 2012 .

Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.

J. Cortes, J. Kolitz, R. Stone, 2016 .

Stable long-term pulmonary function after myeloablative double cord blood transplant.

S. Pergam, L. Newell, J. Gutman, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Graft‐versus‐host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutations

A. Olyaei, S. Orloff, R. Maziarz, 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Mutant calreticulin‐expressing cells induce monocyte hyperreactivity through a paracrine mechanism

B. Druker, A. Agarwal, E. Traer, 2016, American journal of hematology.

Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy

E. Estey, J. Abkowitz, F. Appelbaum, 2015, Leukemia.

Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial

J. Cortes, J. Kolitz, R. Stone, 2016 .

Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors.

W. Wood, B. Storer, J. Pidala, 2016, Blood.

Characteristics of chronic GVHD after cord blood transplantation

M. Flowers, T. Gooley, P. Martin, 2013, Bone Marrow Transplantation.

Follistatin and Soluble Endoglin Predict 1-year Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant.

Jeffrey S. Miller, M. MacMillan, Juan Wu, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

J. Cortes, J. Kolitz, R. Stone, 2016 .

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.

J. Cortes, J. Kolitz, J. Lancet, 2021, The Lancet. Haematology.

Low day +100 serum epidermal growth factor levels are associated with acute GvHD after allogeneic hematopoietic cell transplantation

D. Weisdorf, B. Blazar, M. Verneris, 2017, Bone Marrow Transplantation.

Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.

G. Vercellotti, M. MacMillan, D. Weisdorf, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Robert K. Stuart, Antje Hoering, Arthur C. Louie, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Advances in acute myeloid leukemia

L. Newell, R. Cook, 2021, BMJ.

Placental growth factor: What hematologists need to know.

L. Newell, S. Holtan, 2017, Blood reviews.

Complementary roles for histone deacetylases 1, 2, and 3 in differentiation of pluripotent stem cells.

R. McKay, B. Howard, R. Padmanabhan, 2008, Differentiation; research in biological diversity.

Graft‐versus‐host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutations

A. Olyaei, S. Orloff, R. Maziarz, 2021 .

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia.

R. Collins, S. McWeeney, B. Druker, 2017, Cell reports.

BMPs signal alternately through a SMAD or FRAP–STAT pathway to regulate fate choice in CNS stem cells

Ronald D.G. McKay, R. McKay, D. Panchision, 2003, The Journal of cell biology.

A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias

L. Mayer, R. Stuart, L. Newell, 2019, Cancer Chemotherapy and Pharmacology.

Adult adherent stromal cells in the management of graft-versus-host disease

R. Maziarz, R. Deans, L. Newell, 2014, Expert opinion on biological therapy.

Diurnal stability of cell-free DNA and cell-free RNA in human plasma samples

P. Spellman, Thuy T. M. Ngo, Hyun Ji Kim, 2020, Scientific Reports.

Repairing Damaged Goods: Mesenchymal Stromal Cell Therapy for Secondary Failure of Hematopoiesis Post-Allogeneic Hematopoietic Cell Transplant

S. Markovic, L. Newell, S. Holtan, 2012 .

Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors.

R. Maziarz, L. Newell, S. Slater, 2019, Cytotherapy.

Impact of clinical factors and allograft leukocyte content on post-transplant lymphopenia, monocytopenia, and survival in patients undergoing allogeneic peripheral blood haematopoietic cell transplant

M. Patnaik, W. Hogan, M. Litzow, 2014, BMC Hematology.

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.

W. Wood, J. Pidala, E. Holler, 2018, Blood advances.

Acute GVHD: think before you treat.

L. Newell, S. Holtan, 2021, Hematology. American Society of Hematology. Education Program.

Early CD3 peripheral blood chimerism predicts the long-term engrafting unit following myeloablative double-cord blood transplantation.

S. Heimfeld, T. Gooley, L. Newell, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia

D. Bottomly, S. McWeeney, B. Druker, 2022, Blood advances.

Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML.

J. Cortes, J. Kolitz, J. Lancet, 2020 .

The Bispecific Anti-CD20/CD22 Antibody (Bs20x22) Has More Lymphomacidal Activity Than the Parent Antibodies Both Alone or In Combination

J. Tuscano, L. Newell, Yunpeng Ma, 2010 .

Day 4 collection of granulocyte colony-stimulating factor-mobilized HLA-matched sibling donor peripheral blood allografts demonstrates no long-term increase in chronic graft-versus-host disease or relapse rates.

R. Maziarz, L. Newell, R. Cook, 2023, Cytotherapy.

Therapeutics , Targets , and Chemical Biology CD 22 Antigen IsBroadlyExpressedonLungCancerCells and Is a Target for Antibody-Based Therapy

D. Gandara, D. Pearson, J. Tuscano, 2012 .

Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML

J. Lancet, S. Goldberg, G. Uy, 2022, Blood advances.